Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor CellsBenjamin Boyerinas, Jeffrey Schlom, Christopher R. Heery et al.|Cancer Immunology Research|2015Cited by 456
Phase I Study in Advanced Cancer Patients of a Diversified Prime-and-Boost Vaccination Protocol Using Recombinant Vaccinia Virus and Recombinant Nonreplicating Avipox Virus to Elicit Anti–Carcinoembryonic Antigen Immune ResponsesJohn L. Marshall, Jeffrey Schlom, Robert J. Hoyer et al.|Journal of Clinical Oncology|2000Cited by 357
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialRavi A. Madan, James L. Gulley, Jeffrey Schlom et al.|The Lancet Oncology|2012Cited by 327